Global Partners LP Stock News

NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2026. CEO Commentary “Our third quarter results demonstrate the strength of our integrated liquid energy model, with strong growth in both EBITDA and distributable cash flow year over year,” said Eric Slifka, the Partn...

NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has declared a cash distribution of $0.7850 per unit ($3.14 per unit on an annualized basis) on all of its outstanding common units for the period from July 1, 2026 through September 30, 2026. The distribution ...

GLP-1 drugs have put peptides on investors' radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments.

A new peptide ETF launched today, holding the drugmakers behind GLP-1 weight-loss treatments along with the companies that make and deliver them. Key Takeaways: REX's new fund follows 36 peptide-linked companies, ranging from GLP-1 drugmakers to device and supplement makers.

Rapid weight loss can lead to issues with bone quality, particularly in older adults.

The NBI Thematic Rotation ETF (NTHM:TSX) has completed its latest portfolio rebalance, pivoting away from broad tech and industrial momentum to channel capital into midstream energy infrastructure and GLP-1 weight-loss drug manufacturers. The fund tracks the Thematic Rotation Quality Momentum Screened Index (TRQMS).